Rebecca Kristeleit

ORCID: 0000-0003-3825-1326 · 2 papers in corpus
2025
JAMA oncology ·doi:10.1001/jamaoncol.2024.6797

ImportanceAdvanced clear cell gynecological cancers (CCGCs) have a poor prognosis, with response rates to second-line chemotherapy less than 8%. Preliminary clinical activity with programmed cell death 1 protein (PD-1) inhibitors reported i…

other 2022
Cancer immunology research ·doi:10.1158/2326-6066.CIR-22-0407

Some patients with advanced clear-cell ovarian cancer (CCOC) respond to immunotherapy; however, little is known about the tumor microenvironment (TME) of this relatively rare disease. Here, we describe a comprehensive quantitative and topog…